InvestorsHub Logo
Followers 145
Posts 27561
Boards Moderated 3
Alias Born 02/07/2004

Re: None

Wednesday, 04/10/2024 8:16:44 AM

Wednesday, April 10, 2024 8:16:44 AM

Post# of 3878
RedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (vs US$46.29 loss in FY 2022)

https://finance.yahoo.com/news/redhill-biopharma-full-2023-earnings-102334385.html

editorial-team@simplywallst.com (Simply Wall St)

Wed, April 10, 2024 at 1:23 PM GMT+3

RedHill Biopharma (NASDAQ:RDHL) Full Year 2023 Results
Key Financial Results
Net income: US$23.9m (up from US$71.7m loss in FY 2022).

EPS: US$4.00 (up from US$46.29 loss in FY 2022).

earnings-and-revenue-history
earnings-and-revenue-history
All figures shown in the chart above are for the trailing 12 month (TTM) period

RedHill Biopharma shares are down 6.0% from a week ago.

Risk Analysis
We should say that we've discovered 3 warning signs for RedHill Biopharma (1 doesn't sit too well with us!) that you should be aware of before investing here.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RDHL News